Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma

A two-stage Simon design was used to evaluate the response rate of OSI-7904L, a liposome encapsulated thymidylate synthase inhibitor, in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA), administered intravenously at 12 mg m(−2) over 30 min every 21 days. Fifty patients were treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Falk, S, Anthoney, A, Eatock, M, Van Cutsem, E, Chick, J, Glen, H, Valle, J W, Drolet, D W, Albert, D, Ferry, D, Ajani, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360664/
https://www.ncbi.nlm.nih.gov/pubmed/16880795
http://dx.doi.org/10.1038/sj.bjc.6603267

Ejemplares similares

Ejemplares similares